CTD Holdings Fact Sheet


Published on

CTD Holdings, Inc. companies provide Trappsol® brand cyclodextrins and Aquaplex® brand cyclodextrin complexes to researchers, R&D labs and industrial users in the medical, pharmaceutical, food, and nutritional industries.
The symbol CTDH and trades on the OTCQB.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

CTD Holdings Fact Sheet

  1. 1. OTCQB:CTDHOverviewCTD Holdings, Inc. owns and acquires companiesthat develop, market, (and/or sell) productscontaining cyclodextrins (CDs). Cyclodextrinsare rings of glucose molecules that bring oil andwater together for applications requiring oil andwater to work together seamlessly. Cyclodextrinscan make existing consumer products “new andimproved” by greatly enhancing the bio availabilityof vitamins or minerals and other characteristics.There are a myriad of commercial applications forthis supra-molecular phenomenon including areasof agriculture, analytical chemistry, biotechnology,cosmetics, diagnostics, electronics, foodstuffs,pharmaceuticals, and the remediation of toxic waste.Over the last 20 years, CTD has established itselfas a leading player in the marketing and sale ofcyclodextrin chemistries. In 2010, the Companypurchased a new plant in which to house its highvolume pulse dryer (PD) with which it can manufactureCD complexes in commercial quantities, solving amajor industrial supply challenge and transformingthe Company into a high value, high volume Quick Facts & Key Ratiosmanufacturer. 12-Month Trading Price High $.20 12-Month Trading Price Low $.03 CTD Holdings Inc. Closing Price 10-28-2011 $.13 (United States) Shares Outstanding 8-11-2011 35,515,295 Float 8-11-2011 14,415,396 CTD, Inc. NanoSonic, Sphingo Ferrazo Market Capitalization $4,616,989 Products Biotechnology, Inc. Environmental Enterprise Value $5,430,468 Last Quarter Revenue $369,000 TTM Revenue $1,094,000 Current Assets (Most Recent 10Q or 10K) $452,205 Current Liabilities (Most Recent 10Q or 10K) $226,750 Current Ratio (Most Recent 10Q or 10K) 1.99 x Total Assets (Most Recent 10Q or 10K) $2,385,382 Total Liabilities (Most Recent 10Q or 10K) $955,383 Shareholder Equity (Most Recent 10Q or 10K) $1,429,999
  2. 2. Why Consider Investing in CTD Holdings • Management Team are experts in the cyclodextrin market. • Strong Capital structure, Small Float, Management has lots of skin in the game. • CTD recently completed its new manufacturing plant, allowing it to produce bulk (commercial) amounts of cyclodextrin compounds. • Closed on Credit Facility Package with SunState Federal Credit Union in March 2011. It consists of a $325,000 term loan with a $100,000 revolving line of credit. • Owns a 40 acre farm that is for sale. When sold it will pay off the loan with SunState Federal Credit Union Immediately. • World’s only Cyclodextrin Active Pharmaceutical Ingredient (API) • Orphan Drug Designation, used under Investigational New Drug (IND) • On the EPA National Contingency Plan List- Approved Products • cGMP Manufacturing of Food & Pharmaceutical Grades The Niemann Pick Type C Opportunity At the end of 2008, one of CTD Holdings’ customers provided one of its products in an effort to treat a set of twins in the U.S. who were diagnosed with Niemann Pick C (“NPC”). NPC is also called Childhood Alzheimer’s. It is a fatal disease caused by a genetic defect that prevents proper handling of cholesterol in the body’s cells. Harmful amounts of cholesterol accumulate in the spleen, liver, lungs, bone marrow, and brain. This excess of cholesterol causes progressive neurological deterioration with symptoms including dementia, seizures, ataxia and cataplexy. The patient’s treatment with Hydroxy-propyl-beta-cylcodextrin (HPBCD) (now called Trappsol Cyclo™) proved to provide an ameliorative benefit. On May 17, 2010, the FDA granted orphan drug status for Trappsol Cyclo™ for the treatment of Niemann Pick Type C (NPC) disease to this customer. Under the Orphan Drug Act, companies that develop a drug for a disorder affecting fewer than 200,000 people in the United States may seek designation as an orphan drug and, if such application is approved, they have the ability to sell it without competition for seven years, and may get clinical trial tax incentives. Additional Information CTD Holdings, Inc. 14120 NW 126th Terrace Alachua, FL 32615 (386) 418-8060 www.ctd-holdings.com The WSR Group 3557 SW Corporate Parkway Palm City, FL 34990 (772) 219-7525 Sean Marconi smarconi@theWSRgroup.comImportant Note: This profile may contain forward-looking statements, particularly as related to pro forma financial statements, earnings estimates and business expectations, within the meaning of Section 27A ofthe Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Any statements that express or involve discussions with respectto predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward looking statements.” Forward look-ing statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materiallyfrom those presently anticipated. These forward-looking statements are only made as of the date of their release and CTD Holdings, Inc. does not undertake any obligation to publicly update such forward-lookingstatements to reflect subsequent events or circumstances.